Literature DB >> 9675446

Pharmacodynamics of fluoroquinolones.

H Lode1, K Borner, P Koeppe.   

Abstract

Fluoroquinolone antimicrobial agents are highly active against aerobic or facultative gram-negative bacilli. The fluoroquinolones have been shown to be very concentration dependent in their rates of killing and also have a postantibiotic effect against most gram-negative pathogens. These properties resemble those of aminoglycosides more than those of the beta-lactam antibiotics. In animal studies, once daily administration of a dose that produced a high peak concentration/minimal inhibitory concentration (MIC) ratio of > 10-20:1 resulted in significantly better survival than did regimens in which the same daily dose was used on a more fractionated schedule. Studies in patients, most often with ciprofloxacin, demonstrated that the area under the concentration-time curve (AUC)/MIC ratio (AUIC) is the most important predictor of both clinical and microbiological cure. These findings, when combined with microbiological and pharmacokinetic data, provide the rationale and tools needed for targeting the dosage of fluoroquinolones to individual patients on the basis of pharmacokinetics and the susceptibilities of the bacterial pathogens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9675446     DOI: 10.1086/514623

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  36 in total

1.  Gingival fluid ciprofloxacin levels at healthy and inflamed human periodontal sites.

Authors:  T B Conway; F M Beck; J D Walters
Journal:  J Periodontol       Date:  2000-09       Impact factor: 6.993

2.  The disposition kinetics, urinary excretion and dosage regimen of ciprofloxacin in buffalo calves (Bubalus bubalis).

Authors:  S P Saini; A K Srivastava
Journal:  Vet Res Commun       Date:  2001-12       Impact factor: 2.459

3.  Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.

Authors:  E A Coyle; G W Kaatz; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.

Authors:  Kristina Öbrink-Hansen; Tore Forsingdal Hardlei; Birgitte Brock; Søren Jensen-Fangel; Marianne Kragh Thomsen; Eskild Petersen; Mads Kreilgaard
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

5.  Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis.

Authors:  V Rodriguez-Cerrato; C C McCoig; I C Michelow; F Ghaffar; H S Jafri; R D Hardy; C Patel; K Olsen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

6.  Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.

Authors:  Irma A J M Bakker-Woudenberg; Marian T ten Kate; Luke Guo; Peter Working; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 7.  Pharmacokinetics and pharmacodynamics of antibacterial agents.

Authors:  Matthew E Levison; Julie H Levison
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

Review 8.  New developments in antibacterial choice for lower respiratory tract infections in elderly patients.

Authors:  Anna Maria Ferrara; Anna Maria Fietta
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  Disposition kinetics of levofloxacin in sheep after intravenous and intramuscular administration.

Authors:  Ayman Goudah; Sherifa Hasabelnaby
Journal:  Vet Med Int       Date:  2010-11-02

10.  Disposition kinetics and urinary excretion of ciprofloxacin in goats following single intravenous administration.

Authors:  R Raina; S Prawez; D J Dimitrova; N K Pankaj; P K Verma
Journal:  J Vet Sci       Date:  2008-09       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.